Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction
- 31 October 1998
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 4 (4-5) , 121-129
- https://doi.org/10.1016/s1078-1439(99)00015-0
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Molecular Epidemiology and Retinoid Chemoprevention of Head and Neck CancerJNCI Journal of the National Cancer Institute, 1997
- Mycobacterium Cell Wall: An Alternative to Intravesical Bacillus Calmette Guerin (BCG) Therapy in Orthotopic Murine Bladder CancerJournal of Urology, 1996
- Phase II trials in Ta, T1 bladder cancer. The marker tumour conceptBritish Journal of Urology, 1996
- Strategy for Prevention of Recurrence of Superficial Bladder CancerAktuelle Urologie, 1996
- Factors affecting recurrence and progression in superficial bladder tumoursEuropean Journal Of Cancer, 1995
- INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES?International Journal of Urology, 1995
- THE ETIOLOGY OF BLADDER CANCER-ARE THERE ANY NEW CLUES OR PREDICTORS OF BEHAVIOR?International Journal of Urology, 1995
- Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.Journal of Clinical Pathology, 1994
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986